Pregabalin Completed Phase 3 Trials for Generalized Anxiety Disorder (GAD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00368745Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
NCT00413010Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).